BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ...

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

The company taps its revolving credit facility and cash on hand to broaden its portfolio of global gold deals. The Denver Business Journal will host top health care leaders to discuss the future of ...

XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday.

The firm will continue developing Lava's two partnered bispecific gamma delta T-cell engager programs with Pfizer and Johnson & Johnson.

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

MILWAUKEE, Aug. 4, 2025 /PRNewswire/ — The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for possible breaches of ...

Shares of Hillevax Inc (NASDAQ:HLVX) climbed 2.9% after the company revealed it had entered into a definitive merger ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of HilleVax, Inc. (NASDAQ: HLVX) to XOMA Royalty Corporation is fair to HilleVax shareholders. Under the terms of the ...

Xoma Royalty kicked off the week by buying up a pair of biotechs that have both struggled to recover from recent clinical ...

Under the terms of the agreement, XOMA Royalty will acquire all outstanding shares of Hillevax for $1.95 in cash per share. Shareholders will also receive one non-transferable contingent value right ...

XOMA Royalty Corporation (NASDAQ:XOMA) has unveiled plans to acquire two biotech firms—HilleVax, Inc. (NASDAQ:HLVX) and LAVA ...